# US Biobanking Market

> US Biobanking Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Applications (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations) and By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.52%
- **2024:** $ 21.11 Billion
- **2025:** $ 21.85 Billion
- **2035:** $ 30.87 Billion
- **Key Players:** Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biosample Solutions (US), Global Biobank (GB)

**Report ID:** MRFR/LS/17157-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biobanking-market-18685

---

## Market Summary

## **US Biobanking Market Overview**

As per MRFR analysis, the **US Biobanking Market Size** was estimated at **1.38 (USD Billion) in 2023**. The US Biobanking Market Industry is expected to grow from **1.45 (USD Billion) in 2024** to **2.32 (USD Billion) by 2035**. The US Biobanking Market CAGR (growth rate) is expected to be around **4.365%** during the forecast period (2025 - 2035).

### **Key US Biobanking Market Trends Highlighted**

The US biobanking market is experiencing significant trends driven by advances in genomic research and personalized medicine. The increasing demand for biobanks is largely fueled by the rising prevalence of chronic diseases, which necessitate a deeper understanding of genetic and environmental factors. Additionally, initiatives from government bodies such as the National Institutes of Health support biobanking efforts, pushing for the establishment of comprehensive databases to facilitate cutting-edge research.

This has created opportunities for collaboration among academic institutions, pharmaceuticals, and biotechnology firms to leverage biobanks for drug discovery and development. Opportunities to be explored include the integration of artificial intelligence and machine learning in managing biobanking data, enhancing the ability to analyze vast amounts of biological samples efficiently. There is also a growing trend towards biobanks being recognized not just as storage facilities but as active participants in research networks, promoting transparency and access to diverse populations.

This is important as it ensures that minority groups are also represented in genetic studies, addressing past biases in research. Trends in recent times have also shown an increased focus on ethical considerations in biobanking, emphasizing informed consent and participant privacy. Regulations from the US Department of Health & Human Services reinforce the importance of ethical practices in biobanking, ensuring the protection of individual rights while fostering public trust. Overall, these trends reflect a dynamic US biobanking market that is keen on innovation, collaboration, and ethical responsibility, aiming to advance healthcare outcomes through effective use of biological materials.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Biobanking Market Drivers**

### **Increasing Investments in Research and Development**

The US Biobanking Market Industry is experiencing significant growth driven by escalating investments in Research and Development initiatives. According to the **National Institutes of Health (NIH)**, the US government allocated approximately **41 billion USD** for biomedical research in recent years, fostering advancements that directly impact biobanking practices. This monetary commitment enables the development of innovative technologies for specimen collection, processing, and storage, leading to improved [biobanking](../../../reports/biobanking-market-5967) efficiencies.

Moreover, such increased funding is likely to enhance collaborations between academic institutions and biobanks, resulting in the establishment of unique biorepositories that cater to specific diseases. Companies like **Thermo Fisher Scientific**, specializing in biobanking equipment and services, are leveraging these advancements to create comprehensive solutions for researchers. The alignment of governmental funding with private sector innovations presents a robust foundation for the growth of the US Biobanking Market Industry, signifying its potential to reach new heights in the coming years.

### **Rising Incidence of Chronic Diseases**

The US Biobanking Market Industry is significantly influenced by the growing incidence of chronic diseases, including cancer, diabetes, and cardiovascular conditions. According to the **Centers for Disease Control and Prevention (CDC)**, around **6 in 10 adults in the US have a chronic disease**, and **4 in 10 adults have two or more chronic conditions**. This alarming trend drives the need for extensive biobank collections, as researchers require diverse biological samples to study disease etiology and treatment.

Established biobanks, such as the **Biorepository of the National Cancer Institute**, play a pivotal role in providing access to critical biological specimens for research purposes. By facilitating large-scale genetic studies and clinical trials, biobanks help advance personalized medicine, thereby enhancing the demand for their services. This increased focus on chronic disease research will significantly bolster the US Biobanking Market Industry.

### **Technological Advancements in Biobanking Processes**

The advancement of technology in biobanking, specifically in storage and data management systems, is a driving force behind the growth of the US Biobanking Market Industry. Innovations such as automated sample management systems and advanced cryopreservation techniques have improved specimen quality and integrity. A report from the **Food and Drug Administration (FDA)** highlights that effective data management and tracking of biological samples can enhance research outcomes and ensure regulatory compliance.

Companies like **Qiagen** are innovating to provide solutions that streamline sample processing and enhance the performance of biobanks. Technological improvements not only facilitate better management of biobanks but also promote collaboration between various research entities, making the US Biobanking Market Industry a crucial component of modern biomedical research.

### **Growing Demand for Personalized Medicine**

The shift towards personalized medicine is accelerating the growth of the US Biobanking Market Industry. The **Food and Drug Administration (FDA)** states that personalized medicine uses individual genetic profiles to tailor treatments, which necessitates access to a variety of biological specimens from diverse populations. According to the **Personalized Medicine Coalition**, around **29 million US patients** have received treatments adjusted for their genetic makeup.

Biobanks are essential in providing the samples needed for these targeted therapies, enabling better health outcomes. Companies such as **IBM** and **Genentech** are actively involved in integrating biobanking data with genomic information to foster advancements in precision medicine. This synergy of biobank samples with personalized treatments is likely to drive demand and solidify the US Biobanking Market Industry's role in future healthcare innovation.

## **US Biobanking Market Segment Insights**

### **Biobanking Market Sample Type Insights**

The Sample Type segment of the US Biobanking Market comprises various categories that are crucial for advancing medical research and patient care. This segment includes Blood Products, Tissues, Cells, Nucleic Acids, and Microbiome Samples, each offering distinct advantages for different areas in Research and Development. Blood Products represent a substantial portion of biobanking efforts as they are vital for clinical applications and research on hematological disorders and transfusions. Tissues obtained from various sources are equally important, facilitating the understanding of disease mechanisms and the development of targeted therapies.

Moreover, Cells, including both primary cells and cell lines, play a significant role in regenerative medicine and drug testing, highlighting their relevance in therapeutic innovations. Nucleic Acids, which encompass DNA and RNA samples, are critical for genetic studies, biomarker discovery, and personalized medicine, reflecting the growing trend towards precision health. Additionally, Microbiome Samples have gained attention due to their implications in understanding human health and diseases, particularly in areas like gut health and immunology. Each of these sample types contributes to enhancing the US Biobanking Market's data richness, supporting ongoing studies aimed at improving healthcare outcomes.

Overall, the focus on these diverse sample types exemplifies the broader trends in biobanking, which emphasize the importance of collaboration among researchers, clinicians, and biobank facilities to drive innovation in this essential industry. As biobanks continue to expand their capabilities and collections, they not only contribute to scientific advancements but also address the growing demand for materials that can support a spectrum of research initiatives across the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Biobanking Market Application Insights**

The Application segment of the US Biobanking Market plays a critical role in driving innovation within the healthcare industry. Focused on areas such as Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine, this segment is essential for advancing medical research and improving patient outcomes. Research and Development ensures that new therapeutics are effectively discovered and tested, while Clinical Trials provide the necessary framework for assessing these innovations in real-world settings. Personalized Medicine tailors treatment approaches to individual genetic profiles, offering significant advantages in efficacy and safety compared to traditional methods.

Regenerative Medicine aims to replace or repair damaged cells and tissues, marking a significant shift in treating chronic diseases and injuries. These applications collectively contribute to the market's growth, fueled by increasing investments in biotechnology and supportive government initiatives aimed at enhancing health outcomes in the United States. In this context, the US Biobanking Market segmentation reflects a diverse array of opportunities driven by scientific advancements and the rising need for personalized health solutions in a rapidly evolving healthcare landscape.

### **Biobanking Market End Use Insights**

The US Biobanking Market has demonstrated significant growth potential, particularly within the End Use segment, which encompasses various crucial entities such as Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a pivotal role in advancing biomedical research by providing essential biological samples, which support numerous studies and enhance the understanding of complex diseases. Biotechnology Companies often rely on biobanks for critical testing and development of novel therapeutics, fostering innovation in the industry.

Pharmaceutical Companies leverage biobanks to facilitate drug development processes, ensuring efficient translation of research findings into actionable treatments. Government Organizations contribute by supporting biobanking initiatives that aim to advance public health initiatives, disease prevention, and environmental studies. The collective efforts of these entities underscore the importance of biobanking in driving medical research, improving patient outcomes, and forming a foundation for the development of new healthcare solutions. As the focus on personalized medicine and genetic research continues to grow, these sectors are expected to play increasingly vital roles in shaping the US Biobanking Market landscape.

Furthermore, challenges and opportunities concerning data management, ethical considerations, and regulatory frameworks remain intrinsic to the evolution of biobanking practices in the United States.

### **Biobanking Market Storage Type Insights**

The Storage Type segment of the US Biobanking Market is critical for enabling effective long-term preservation of biological samples, which is fundamental for research and clinical applications. Vapor Phase Storage is increasingly favored due to its efficient nitrogen usage and lower risk of contamination, making it suitable for sensitive cell lines and biological specimens. Liquid Phase Storage, while traditionally employed, is witnessing a transformation with advancements in technology that enhance its reliability for sample integrity.

Cryopreservation Storage plays a significant role in the market as it facilitates the preservation of cells, tissues, and organs at extremely low temperatures, enabling successful long-term storage.

This technique is essential for maintaining the viability of samples for extended periods, ensuring that biobanks can support various applications, including Research and Development activities. As the US faces a growing demand for personalized medicine and advanced therapies, the importance of effective storage solutions cannot be understated, making this segment a key driver of US Biobanking Market growth. Overall, the diversity of storage methods and their evolving technologies highlight the market's adaptability to changing scientific needs and the pursuit of innovation.

## **US Biobanking Market Key Players and Competitive Insights**

The US Biobanking Market is an essential component of the healthcare and research landscape, driven by advancements in biotechnologies and genetic research. The competitive insights within this sector reveal a dynamic environment where various players are constantly innovating to meet the growing demand for biobanks and biorepositories. Factors such as technological advancements, regulatory frameworks, and collaborations between academic, public, and private sectors significantly impact competition. The crucial role of biobanks in personalized medicine, drug discovery, and disease research creates a lucrative market for stakeholders, each aiming to capture a share through unique offerings, efficient operations, and strategic partnerships.

With a profound emphasis on quality, compliance, and data management, companies in the biobanking space must continuously adapt to the evolving needs of researchers and pharmaceutical companies.

### **Molecular X**

Molecular X has established itself as a formidable player in the US Biobanking Market, focusing on the collection, storage, and distribution of biological samples. The company is recognized for its robust operational capabilities and has developed advanced techniques that ensure sample integrity while maintaining high ethical standards. Molecular X's strong presence in the US can be attributed to its commitment to quality control and innovative storage solutions, which lend credibility to the biobanks it operates. Additionally, its strategic collaborations with leading research institutions and healthcare organizations enhance its market standing, fostering trust and reliability.

The company's emphasis on cutting-edge technology not only streamlines the biobanking process but also expands its range of services, positioning it well against competitors in this evolving landscape.

### **Global BioResource**

Global BioResource is another key player within the US Biobanking Market, offering a comprehensive range of products and services designed to support research and clinical applications. The company's portfolio includes biologic sample collection, biorepository management software, and analytical services that cater to a diverse clientele. Global BioResource's market presence has been strengthened by its strategic mergers and acquisitions, which have expanded its operational capabilities and geographic reach within the US. The company's strengths lie in its innovative approaches to sample processing, efficient logistics, and data management, making it an attractive partner for research institutions and pharmaceutical companies alike.

With a strong focus on compliance and quality assurance, Global BioResource has positioned itself as a trusted resource in the biobanking sector, enabling researchers to access high-quality biological materials essential for advancing scientific discoveries.

### **Key Companies in the US Biobanking Market Include**

## **US Biobanking Market Industry Developments**

The US Biobanking Market has witnessed significant advancements and changes recently. Companies like **Molecular X** and **Global BioResource** are focusing on expanding their biobanking capabilities to cater to the rising demand for personalized medicine and genomic research. In recent developments, **PerkinElmer** has launched innovative solutions aimed at enhancing sample analysis and storage efficiency, while **Thermo Fisher Scientific** continues to enhance its infrastructure to support biobanks across the nation. 

A notable merger occurred in **August 2023**, when **BD** acquired a biotechnology firm that specializes in biobank solutions, strengthening its position in the market. Additionally, companies such as **SeraCare Life Sciences** and **Brooks Life Sciences** are driving growth through technological innovations in sample management and storage systems. The market valuation is also experiencing an uptick due to increased investment in biobanking initiatives, reflecting a strong demand for high-quality biospecimens in clinical trials and research. Overall, the US Biobanking Market continues to evolve with robust participation from key players while maintaining a focus on advancing healthcare outcomes through meticulous biobanking processes.

## **US Biobanking Market Segmentation Insights**

### **Biobanking Market Sample Type Outlook**

### **Biobanking Market Application Outlook**

### **Biobanking Market End Use Outlook**

### **Biobanking Market Storage Type Outlook**

## Market Drivers

### Regulatory Support and Frameworks

Regulatory support plays a crucial role in shaping the biobanking market, particularly in the US. The establishment of clear guidelines and frameworks by regulatory bodies facilitates the ethical collection, storage, and use of biological samples. Recent initiatives aimed at harmonizing regulations across states are likely to enhance operational efficiency for biobanks. This regulatory clarity encourages investment and participation from both public and private sectors, as stakeholders feel more secure in their compliance with legal standards. Furthermore, supportive regulations can lead to increased funding opportunities for biobanks, enabling them to expand their capabilities and services. As the regulatory landscape evolves, it is expected to significantly influence the growth trajectory of the biobanking market.

### Rising Demand for Personalized Medicine

The biobanking market is experiencing a notable surge in demand for personalized medicine, driven by advancements in genomics and biotechnology. As healthcare shifts towards tailored treatments, biobanks play a crucial role in providing the necessary biological samples for research and development. In the US, the market for personalized medicine is projected to reach approximately $350 billion by 2025, indicating a robust growth trajectory. This trend underscores the importance of biobanks in facilitating the discovery of biomarkers and therapeutic targets, thereby enhancing patient outcomes. The integration of biobanking with personalized medicine not only supports clinical trials but also fosters innovation in drug development, making it a pivotal driver in the biobanking market.

### Growing Public Awareness and Participation

Public awareness regarding the importance of biobanking is steadily increasing, which is positively impacting the biobanking market. Educational campaigns and outreach programs are encouraging individuals to participate in biobanking initiatives, thereby expanding the pool of available biological samples. In the US, participation rates in biobanking studies have shown a marked increase, with some studies reporting engagement levels of over 30%. This growing public interest not only enhances the diversity of samples but also supports research in various fields, including cancer, rare diseases, and genetic disorders. As more individuals recognize the value of contributing to biobanks, the overall growth and sustainability of the biobanking market are likely to be bolstered.

### Technological Integration and Data Management

The integration of advanced technologies in biobanking is transforming the landscape of the biobanking market. Innovations such as artificial intelligence, machine learning, and blockchain are enhancing data management and sample tracking capabilities. In the US, biobanks are increasingly adopting these technologies to streamline operations and improve sample integrity. For instance, AI-driven analytics can optimize sample selection for research, while blockchain ensures secure and transparent data sharing. This technological evolution not only increases operational efficiency but also enhances the reliability of biobanked samples, making them more valuable for researchers. As technology continues to advance, its impact on the biobanking market is expected to grow, driving further investment and development.

### Increased Investment in Research and Development

Investment in research and development (R&D) is a significant driver of the biobanking market, particularly in the US. With federal funding and private sector investments on the rise, biobanks are becoming essential resources for researchers. In 2025, R&D spending in the life sciences sector is expected to exceed $200 billion, with a substantial portion allocated to biobanking initiatives. This influx of capital enables the establishment of new biobanks and the expansion of existing facilities, enhancing their capacity to store and manage biological samples. Furthermore, increased R&D investment fosters collaboration between academic institutions and biobanks, leading to innovative research projects that leverage biobanked materials for groundbreaking discoveries.

## Future Outlook

The [Biobanking Market](https://www.marketresearchfuture.com/reports/biobanking-market-5967) is projected to grow at a 3.52% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased research funding, and technological innovations.

**New opportunities:**

- Expansion of biorepository services for rare diseases
- 
- Development of automated sample processing systems
- Partnerships with pharmaceutical companies for drug discovery initiatives

By 2035, the biobanking market is expected to achieve robust growth and enhanced strategic positioning.

## Segment Insights

### By Sample Type: Blood Products (Largest) vs. Cells (Fastest-Growing)

In the US [biobanking market](https://www.marketresearchfuture.com/reports/biobanking-market-5967), Blood Products hold the largest share among the sample types, reflecting their critical role in medical research and therapies. Tissues, Cells, Nucleic Acids, and Microbiome Samples also represent significant portions of the market share, but they trail behind in comparison to Blood Products. Each sample type functions within unique niches, catering to diverse research requirements, but Blood Products continue to lead in volume and utilization. Growth trends in the sample type segment reveal a shift towards increased use of Cells, particularly due to advancements in cell-based therapies and regenerative medicine. The demand for Nucleic Acids and Microbiome Samples is also rising, driven by ongoing research in genomics and microbiomics. Regulatory factors and increased funding for biobanking initiatives contribute to this growth trajectory, with emerging applications paving the way for further market expansion.

Blood Products: Dominant vs. Cells: Emerging

Blood Products are the dominant force in the US biobanking market, primarily due to their essential role in transfusion medicine, clinical trials, and personalized medicine. They are well-established in biobanks, processed for various therapeutic applications, and maintained under stringent regulatory standards. Cells represent an emerging segment, fueled by innovations in cell therapy, stem cell research, and regenerative medicine. Their adaptability for various applications is increasing their appeal among researchers. Both segments face challenges, such as maintaining the integrity of samples during collection and storage, yet the growth in demand for personalized and precision medicine opens new opportunities for both Blood Products and Cells.

### By Application: Research and Development (Largest) vs. Regenerative Medicine (Fastest-Growing)

In the US biobanking market, the application segment exhibits a diverse distribution with a significant share held by Research and Development, which is a pivotal driver for biobanking initiatives. Clinical Trials also contribute substantially, utilizing biobanks for patient samples and data, while Personalized Medicine approaches are gaining traction as precision treatments evolve. Regenerative Medicine, though currently a smaller segment, is rapidly gaining interest due to advancements in cell therapy and tissue engineering. Growth trends within the application segment are influenced by several factors, including increasing investment in biomedical research and the rising demand for personalized healthcare solutions. The push for precision medicine is driving interest in biobanking for patient-specific therapies, while Clinical Trials continue to require robust biobanking for research integrity. Meanwhile, the emergence of Regenerative Medicine is characterized by innovative research, attracting both funding and collaboration from various sectors, ensuring that it remains the fastest-growing area in this market.

Research and Development (Dominant) vs. Regenerative Medicine (Emerging)

Research and Development stands as the dominant application within the US biobanking market, primarily due to its foundational role in advancing scientific knowledge and drug discovery. This segment thrives on extensive sample collection and data analysis, enabling breakthroughs in various medical fields. In contrast, Regenerative Medicine is an emerging area that focuses on repairing or replacing damaged cells and tissues. As this field progresses, driven by advancements in stem cell research and other innovative therapies, it is attracting significant investment and research focus, positioning it as a vital area with immense potential for future developments, thereby further diversifying the applications of biobanked materials.

### By End-use: Academic Research Institutions (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

The market share distribution within the US biobanking market highlights the prominence of Academic Research Institutions, which hold the largest share due to their continuous need for biological samples to support extensive research initiatives. In contrast, Pharmaceutical Companies are rapidly gaining ground, driven by their essential role in drug development and the shift toward personalized medicine, which necessitates vast repositories of biological materials for clinical trials and research purposes. Growth trends in the segment reveal a robust increasing demand for biobanking services across both Academic Research Institutions and Pharmaceutical Companies. The proliferation of biobanks is spurred by advancements in genomics and biotechnology, enhancing research capabilities. Additionally, the focus on precision medicine and the increasing investment in R&D are propelling Pharmaceutical Companies to establish larger biobanking facilities, thus driving the segment's growth trajectory further.

Academic Research Institutions (Dominant) vs. Pharmaceutical Companies (Emerging)

Academic Research Institutions dominate the landscape of the US biobanking market due to their vital role in supporting academic research and development programs. These institutions utilize biobanks to gather and preserve biological specimens necessary for scientific inquiries, contributing significantly to innovation in healthcare and medicine. Conversely, Pharmaceutical Companies are emerging players as they increasingly leverage biobanking to enhance drug discovery processes and clinical trial efficiency. These companies are investing in state-of-the-art biobanking technologies to optimize specimen management and ensure high-quality samples, positioning themselves favorably in the competitive market. As the demand for personalized and targeted therapies accelerates, both segments are expected to adapt and thrive in the evolving landscape.

### By Storage Type: Liquid Phase Storage (Largest) vs. Cryopreservation Storage (Fastest-Growing)

In the US biobanking market, the primary share of the storage types is dominated by Liquid Phase Storage, known for its efficient preservation of biological materials at temperatures below -150°C. It holds a significant portion of the market due to its established reliability and performance. This segment's extensive application in various biobanks underlines its pivotal role in ensuring sample integrity over long durations, making it a preferred choice among researchers and institutions. On the other hand, Cryopreservation Storage is emerging rapidly, gaining traction due to advancements in technology and an increasing demand for stem cell research and regenerative medicine. This segment is driven by innovations in freezing techniques and improved storage solutions that enhance cell viability after thawing. As researchers continue to explore new applications, the growth of Cryopreservation Storage is expected to accelerate, positioning it as a crucial player in the market.

Liquid Phase Storage (Dominant) vs. Cryopreservation Storage (Emerging)

Liquid Phase Storage stands out as the dominant storage method, known for its capacity to maintain samples at extremely low temperatures, thus ensuring long-term preservation of biological specimens. This method is widely adopted across commercial and academic biobanks, reflecting its reliability. In contrast, Cryopreservation Storage, while currently an emerging alternative, showcases potential for swift growth driven by innovations aimed at improving cellular preservation before and after thawing. This segment is particularly pivotal for sectors focused on regenerative medicine and cellular therapies, indicating a shift towards more flexible and adaptable storage methods. As scientific research evolves, both storage types will likely coexist, meeting varying demands in the biobanking domain.

## Competitive Benchmarking

The biobanking market is currently characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for personalized medicine, and a growing emphasis on research and development. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Qiagen (DE) are at the forefront, leveraging their extensive portfolios to enhance operational capabilities. Thermo Fisher Scientific (US) focuses on innovation through the development of advanced biobanking solutions, while Illumina (US) emphasizes genomic technologies to support biobanking initiatives. Qiagen (DE) is strategically positioned through partnerships aimed at expanding its product offerings, thereby shaping a competitive environment that is increasingly reliant on technological advancements and collaborative efforts.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Thermo Fisher Scientific (US) and Illumina (US) suggests a trend towards consolidation, as these firms seek to strengthen their market positions through strategic acquisitions and partnerships.
In October Thermo Fisher Scientific (US) announced a partnership with a leading research institution to develop a new biobanking platform that integrates AI-driven analytics. This strategic move is likely to enhance their product offerings and position them as a leader in the biobanking sector, particularly in the realm of data management and analysis. The integration of AI is expected to streamline operations and improve the accuracy of biobanking processes, thereby attracting more clients.
In September Illumina (US) launched a new suite of genomic sequencing tools specifically designed for biobanking applications. This initiative not only reinforces Illumina's commitment to innovation but also addresses the growing demand for high-throughput sequencing technologies in biobanking. By enhancing their product line, Illumina (US) is likely to capture a larger share of the market, appealing to research institutions and biobanks seeking cutting-edge solutions.
In August Qiagen (DE) expanded its biobanking services through the acquisition of a smaller biobanking firm specializing in sample preservation technologies. This acquisition is indicative of Qiagen's strategy to broaden its service offerings and enhance its competitive edge. By integrating new technologies and expertise, Qiagen (DE) is positioned to better serve its clients and respond to the evolving needs of the biobanking market.
As of November current trends in the biobanking market include a strong focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver customized solutions. This shift suggests that companies that prioritize R&D and strategic partnerships will likely emerge as leaders in the biobanking market.

## Recent News & Developments

The US Biobanking Market has witnessed significant advancements and changes recently. Companies like **Molecular X** and **Global BioResource** are focusing on expanding their biobanking capabilities to cater to the rising demand for personalized medicine and genomic research. In recent developments, **PerkinElmer** has launched innovative solutions aimed at enhancing sample analysis and storage efficiency, while **Thermo Fisher Scientific** continues to enhance its infrastructure to support biobanks across the nation. 

A notable merger occurred in **August 2023**, when **BD** acquired a biotechnology firm that specializes in biobank solutions, strengthening its position in the market. Additionally, companies such as **SeraCare Life Sciences** and **Brooks Life Sciences** are driving growth through technological innovations in sample management and storage systems. The market valuation is also experiencing an uptick due to increased investment in biobanking initiatives, reflecting a strong demand for high-quality biospecimens in clinical trials and research. Overall, the US Biobanking Market continues to evolve with robust participation from key players while maintaining a focus on advancing healthcare outcomes through meticulous biobanking processes.

## Report Scope

| MARKET SIZE 2024 | 21.11(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 21.85(USD Billion) |
| MARKET SIZE 2035 | 30.87(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biosample Solutions (US), Global Biobank (GB) |
| Segments Covered | Sample Type, Application, End-use, Storage Type |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative biobanking solutions and technologies. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the biobanking market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US biobanking market in 2024?**
A: The US biobanking market was valued at $21.11 Billion in 2024.

**Q: What is the projected market valuation for the US biobanking market by 2035?**
A: The market is projected to reach $30.87 Billion by 2035.

**Q: What is the expected CAGR for the US biobanking market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US biobanking market during 2025 - 2035 is 3.52%.

**Q: Which segment of the US biobanking market had the highest valuation in 2024?**
A: In 2024, the Nucleic Acids segment had the highest valuation at $5.0 Billion.

**Q: What are the projected values for Blood Products in the US biobanking market by 2035?**
A: Blood Products are projected to reach $5.0 Billion by 2035.

**Q: Which application segment is expected to grow the most in the US biobanking market by 2035?**
A: The Research and Development application segment is expected to grow to $12.15 Billion by 2035.

**Q: What is the projected market size for Pharmaceutical Companies in the US biobanking market by 2035?**
A: Pharmaceutical Companies are projected to reach $10.0 Billion by 2035.

**Q: What storage type is expected to have the highest valuation in the US biobanking market by 2035?**
A: Cryopreservation Storage is expected to have the highest valuation at $12.87 Billion by 2035.

**Q: Who are the key players in the US biobanking market?**
A: Key players include Thermo Fisher Scientific, Qiagen, Illumina, and Merck KGaA.

**Q: What is the projected value for Microbiome Samples in the US biobanking market by 2035?**
A: Microbiome Samples are projected to reach $8.27 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biobanking-market-18685*